These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33811643)

  • 1. Measures of longitudinal adherence to fecal-based colorectal cancer screening: Literature review and recommended approaches.
    Doria-Rose VP; Lansdorp-Vogelaar I; McCarthy S; Puricelli-Perin DM; Butera V; Segnan N; Taplin SH; Senore C
    Int J Cancer; 2021 Jul; 149(2):316-326. PubMed ID: 33811643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal Adherence to Immunochemical Fecal Occult Blood Testing vs Guaiac-based FOBT in an Organized Colorectal Cancer Screening Program.
    Benito L; Travier N; Binefa G; Vidal C; Espinosa J; Milà N; Garcia M
    Cancer Prev Res (Phila); 2019 May; 12(5):327-334. PubMed ID: 30890542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk prediction for advanced neoplasia using longitudinal adherence measures to fecal immunochemical test-based colorectal cancer screening programs.
    de Jonge L; Riggi E; van Duuren LA; Toes-Zoutendijk E; Campari C; Sassatelli R; Arrigoni A; Orione L; Lansdorp-Vogelaar I; Senore C
    Prev Med; 2023 May; 170():107488. PubMed ID: 36931473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to national guidelines for colorectal cancer screening in Israel: Comprehensive multi-year assessment based on electronic medical records.
    Paltiel O; Keidar Tirosh A; Paz Stostky O; Calderon-Margalit R; Cohen AD; Elran E; Valinsky L; Matz E; Krieger M; Yehuda AB; Jaffe DH; Manor O
    J Med Screen; 2021 Mar; 28(1):25-33. PubMed ID: 32356670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. USPSTF colorectal cancer screening guidelines: an extended look at multi-year interval testing.
    Berger BM; Parton MA; Levin B
    Am J Manag Care; 2016 Feb; 22(2):e77-81. PubMed ID: 26881323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for colorectal cancer: current status in Japan.
    Saito H
    Dis Colon Rectum; 2000 Oct; 43(10 Suppl):S78-84. PubMed ID: 11052482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal adherence to fecal occult blood testing impacts colorectal cancer screening quality.
    Gellad ZF; Stechuchak KM; Fisher DA; Olsen MK; McDuffie JR; Ostbye T; Yancy WS
    Am J Gastroenterol; 2011 Jun; 106(6):1125-34. PubMed ID: 21304501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of participation over four rounds of annual fecal immunochemical test-based screening for colorectal cancer: what predicts rescreening?
    Osborne JM; Wilson C; Duncan A; Cole SR; Flight I; Turnbull D; Hughes DL; Young GP
    BMC Public Health; 2017 Aug; 18(1):81. PubMed ID: 28764667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reasons for never and intermittent completion of colorectal cancer screening after receiving multiple rounds of mailed fecal tests.
    Green BB; BlueSpruce J; Tuzzio L; Vernon SW; Aubree Shay L; Catz SL
    BMC Public Health; 2017 May; 17(1):531. PubMed ID: 28558663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the impact of differential adherence on the comparative effectiveness of stool-based colorectal cancer screening using the CRC-AIM microsimulation model.
    Piscitello A; Saoud L; Fendrick AM; Borah BJ; Hassmiller Lich K; Matney M; Ozbay AB; Parton M; Limburg PJ
    PLoS One; 2020; 15(12):e0244431. PubMed ID: 33373409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal Occult Blood Tests in Colorectal Cancer Screening: Systematic Review and Meta-analysis of Traditional and New-generation Fecal Immunochemical Tests.
    Meklin J; SyrjÄnen K; Eskelinen M
    Anticancer Res; 2020 Jul; 40(7):3591-3604. PubMed ID: 32620599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunochemical fecal occult blood tests for colorectal cancer screening: Point-of-care tests are not tenable for a quality-assured program].
    Haug U; Becker N
    Dtsch Med Wochenschr; 2016 May; 141(10):729-31. PubMed ID: 27176068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review of colorectal cancer screening guidelines for average-risk adults: Summarizing the current global recommendations.
    Bénard F; Barkun AN; Martel M; von Renteln D
    World J Gastroenterol; 2018 Jan; 24(1):124-138. PubMed ID: 29358889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survey of internal medicine residents' use of the fecal occult blood test and their understanding of colorectal cancer screening and surveillance.
    Sharma VK; Corder FA; Raufman JP; Sharma P; Fennerty MB; Howden CW
    Am J Gastroenterol; 2000 Aug; 95(8):2068-73. PubMed ID: 10950059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From guaiac to immune fecal occult blood tests: the emergence of technology in colorectal cancer screening.
    Greenwald B
    Gastroenterol Nurs; 2005; 28(2):90-6. PubMed ID: 15832108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The usefulness of fecal tests in colorectal cancer screening].
    Castells A
    Gastroenterol Hepatol; 2014 Sep; 37 Suppl 3():71-6. PubMed ID: 25294268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mental Illness Is Not Associated with Adherence to Colorectal Cancer Screening: Results from the California Health Interview Survey.
    Siantz E; Wu B; Shiroishi M; Vora H; Idos G
    Dig Dis Sci; 2017 Jan; 62(1):224-234. PubMed ID: 27822771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A centralized mailed program with stepped increases of support increases time in compliance with colorectal cancer screening guidelines over 5 years: A randomized trial.
    Green BB; Anderson ML; Cook AJ; Chubak J; Fuller S; Meenan RT; Vernon SW
    Cancer; 2017 Nov; 123(22):4472-4480. PubMed ID: 28753230
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.